Novo nordisk – repaglinide combination patent invalid

Yesterday, The district court of Michigan ruled that OB listed 6,677,358 (exp: Jun 12, 2018) patent is invalid and unenforceable.

Press release

“… The district court ruled that the patent, which covers the combination use of repaglinide and metformin for the treatment of type 2 diabetes, is invalid and unenforceable … ” “…We are disappointed with today’s ruling. We believe that it is contrary to the evidence and we intend to appeal the ruling,” says Jesper Brandgaard, executive vice president and chief financial officer of Novo Nordisk…”

The ANDA applicant who involved in trial, is Carco Pharma Subs of Sun pharmaceuticals.

Note: For the same product, there is a dispute on patent (‘358) and their use code and section viii label carve out.

About Guna

Interested to learn things around me
This entry was posted in Daily interesting IP news, Patent case and tagged , , , , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s